19
DEC
2016

NW Bio Announces Initiation Of Trading On The OTCQB Marketplace Starting On Monday Morning, December 19, 2016

Posted By :
Comments : Off
BETHESDA, Md., December 19, 2016 – Northwest Biotherapeutics (Nasdaq: NWBO) (“NW Bio” or the “Company”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that its common stock will begin trading on the OTC Market Group’s OTCQB marketplace effective at the open of the market on Monday, December 19, 2016.  The Trading symbol will remain NWBO. As of this morning, t...
Read More
08
DEC
2016

NW Bio Provides Update About Phase 3 Trial Of DCVax®-L for Newly Diagnosed Glioblastoma Multiforme Brain Cancer

Posted By :
Comments : Off
Trial Enrolled 331 Patients; Data “Events” Accumulating Towards Trial Endpoints BETHESDA, Md., December 8, 2016 – Northwest Biotherapeutics (Nasdaq: NWBO) (“NW Bio” or the “Company”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided an update about the Company’s Phase 3 trial of DCVax®-L for Glioblastoma multiforme (GBM) brain cancer (the “Trial”).  The Company announced...
Read More
07
DEC
2016

NW Bio Announces Decision to Voluntarily Withdraw from Nasdaq Listing and Begin Trading on OTC Market

Posted By :
Comments : Off
BETHESDA, Md., December 7, 2016 – Northwest Biotherapeutics (Nasdaq: NWBO) (“NW Bio” or the “Company”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Nasdaq Staff has not accepted the Company’s plan of remediation for certain violations of Listing Rules previously reported, and the Company has notified Nasdaq of its intention to voluntarily withdraw t...
Read More
17
NOV
2016

NW Bio Announces Phase II Clinical Trial Program Combining DCVax®-L and Pembrolizumab (Keytruda®) for Colorectal Cancer

Posted By :
Comments : Off
Trial to Be Led By University Of Mainz Center of Excellence BETHESDA, MD, November 17, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today joined the University Medical Center (UMC) of the Johannes Gutenberg University Mainz in Germany in announcing a Phase II clinical trial program combining DCVax®-L and Pembrolizumab...
Read More
21
OCT
2016

NW BIO Announces Registered Direct Offering

Posted By :
Comments : Off
BETHESDA, Md., October 21, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a definitive agreement with an institutional investor for a registered direct offering with gross proceeds of approximately $5million. The proceeds will be used in connection with upcoming Phase II clinical trials....
Read More